Mirum Pharmaceuticals Valuation Multiples

Mirum Pharmaceuticals Overview

About Mirum Pharmaceuticals

Mirum Pharmaceuticals Inc is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of novel therapies for debilitating rare and orphan diseases. Its product, Livmarli, a novel, orally administered, minimally-absorbed ileal bile acid transporter IBAT) inhibitor (IBATi), is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome (ALGS). It is involved in the development of Maralixibat for the treatment of pediatric patients with progressive familial intrahepatic cholestasis, or PFIC, and Alagille syndrome, or ALGS. The company is also involved in the development of volixibat for the treatment of adult patients with cholestatic liver diseases.

Founded

2018

HQ

Employees

372

Website

mirumpharma.com

Sectors

BiopharmaceuticalsBioTech

Financials (LTM)

Revenue: $558M

EBITDA: ($26M)

EV

$6B

Valuation Multiples

Multiples.vc

Start free trial

Mirum Pharmaceuticals Financials

Mirum Pharmaceuticals reported last 12-month revenue of $558M and negative EBITDA of ($26M).

In the same LTM period, Mirum Pharmaceuticals generated $449M in gross profit, ($26M) in EBITDA losses, and had net loss of ($44M).

Mirum Pharmaceuticals P&L

In the most recent fiscal year, Mirum Pharmaceuticals reported revenue of $521M and EBITDA of $17M.

Mirum Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

Mirum Pharmaceuticals Stock Performance

Mirum Pharmaceuticals has current market cap of $6B, and enterprise value of $6B.

Mirum Pharmaceuticals' stock price is $97.95.

Mirum Pharmaceuticals Valuation Multiples

Mirum Pharmaceuticals trades at 10.5x EV/Revenue multiple, and (229.3x) EV/EBITDA.

Mirum Pharmaceuticals Financial Valuation Multiples

As of April 19, 2026, Mirum Pharmaceuticals has market cap of $6B and EV of $6B.

Equity research analysts estimate Mirum Pharmaceuticals' 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

Mirum Pharmaceuticals has a P/E ratio of (134.3x).

Mirum Pharmaceuticals Margins & Growth Rates

Mirum Pharmaceuticals' revenue in the last 12 month grew by 23%.

Mirum Pharmaceuticals' revenue per employee in the last FY averaged $1.4M, while opex per employee averaged $1.2M for the same period.

Mirum Pharmaceuticals' rule of 40 is 9% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Mirum Pharmaceuticals' rule of X is 44% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Mirum Pharmaceuticals Public Comps

See public comps and valuation multiples for other Biopharmaceuticals comps.

Mirum Pharmaceuticals M&A Activity

Mirum Pharmaceuticals acquired XXX companies to date.

Last acquisition by Mirum Pharmaceuticals was on XXXXXXXX, XXXXX. Mirum Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).

Mirum Pharmaceuticals Investment Activity

Mirum Pharmaceuticals invested in XXX companies to date.

Mirum Pharmaceuticals made its latest investment on XXXXXXXX, XXXXX. Mirum Pharmaceuticals invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).